The MEDINA Foundation and group FERRER announce their collaboration in the discovery of new antibiotics.

The MEDINA Foundation has one of the collections of aktinomycetes, bacteria and filamentous fungi most productive worldwide that offers drug discovery. MEDINA has the experience and the historical ties with some of the discoveries in most relevant natural products of recent decades. On the basis of this long history of success in the identification of compounds of microbial origin with potential for their development as drugs that MEDINA was established as a unique platform for the discovery of natural products and an opportunity to identify new chemical entities unknown in libraries of molecules of synthesisthat can respond to medical needs not covered in infectious diseases.

Group FERRER brings to this collaboration a trajectory of first class in the discovery and development of new anti-infective agents. FERRER is currently developing two new anti-infective agents: Ozenoxacin, a new quinolone non-fluoridated with unique activity profile is being developed for the treatment of infections (phase III) topical, and Arasertaconazol, a new antifungal class of antifungals for vulvo-vaginal infections (phase II). FERRER has recently refocused its programmes of discovery of anti-infective towards the search for new indications niche, which has sought sources of natural products of the first order.

This agreement represents a strategic collaboration for the identification of new drugs in the area of infectious diseases from a single source such as natural products of the MEDINA Foundation ” Dr Olga Genilloud, Fundación MEDINA, Director science. are convinced that MEDINA provides in collaboration with Ferrer experience and the necessary tools to enable the highest probability of success in the discovery of new antibiotics for the treatment of serious infections caused by Multiresistant bacteria ”.

We are very excited in collaboration with the Fundación MEDINA, a recognized expert in the field of the discovery of drugs from natural products. This collaboration will allow us to supplement our drug discovery programs with new candidates for the development of new composite antiinfectives. ” Dr Antonio Guglietta, Ferrer, Director of r & d

Fundación MEDINA

MEDINA Foundation is a research centre non-profit established in Granada from the public-private consortium between the Junta de Andalucía, the University of Granada and Merck Sharp and Dohme of Spain S.A.. The MEDINA Foundation has one of the largest and more various collections of natural products of microbial origin, with a long history of success in the generation of new candidates for drugs for the pharmaceutical sector. The MEDINA Foundation has extensive experience in microbiology and chemistry of natural products, with its screening of high density, and is developing drug discovery programs in infectious diseases (including tuberculosis and parasitic diseases), Oncology, and rare diseases. The MEDINA Foundation is establishing agreements and research collaborations with pharmaceutical and biotechnology companies for the discovery of new therapeutic compounds of microbial origin.

Group Ferrer

Grupo Ferrer is a global pharmaceutical company founded in 1940 in Barcelona. Since its establishment the company has invested in research and development of innovative medicines, as well as build a solid industrial structure. The company has focused its investments in strategic areas such as pharmaceuticals, food and fine chemistry, three key sectors that contribute to improving health and quality of life of the population.

In 1977 r & d group Ferrer was substantially reinforced with the establishment of its research center in Barcelona. The Centre has more than 140 researchers working primarily in the discovery and development of medications in therapeutic areas such as central nervous system, the anti-infective and the inflammation.